ADx logo

ALZHEIMER'S DISEASE AND DEMENTIA
IS A WORLDWIDE CHALLENGE
 

TODAY, NO CURE IS AVAILABLE

ADx NeuroSciences presenting at the AAIC, Washington

Researchers from ADx have been involved in many Alzheimer biomarker studies. This resulted in 7 posters and 4 oral presentations at the upcoming Alzheimer conference in Washington, July 18-23.

 

Two posters were selected as a new developing topic:

 

  • Cerebrospinal fluid Aß42/Aß40 and Aß42/Aß38 ratios: improved biomarkers of Alzheimer’s disease.

 

  • A monoclonal antibody based ELISA for neurogranin.

 

An overview of the 11 posters and presentations can be found here.

Read More

ADx NeuroSciences develops and delivers:

Detection tools for precise, early and successful intervention:

Development of own proprietary stand-alone biomarkers and in-licensing of newly discovered markers from academic and industrial partners.

Companion diagnostics for improved and efficient drug development:

Development and co-development of tailor-made new generation companion diagnostics for neurodegenerative disorders.

Read More